表紙
市場調查報告書
商品編碼
1017592

腫瘤學治療藥 (癌症治療藥) 市場 - 目前分析與預測:2021年∼2027年

Oncology Therapeutics Market: Current Analysis and Forecast (2021-2027)

出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

腫瘤藥物主要用於手術、化學療法、放射療法和標靶療法治療癌症。癌症患病率的增加、老年人口的增加、研發計劃的增加、私人和公共資金以及政府患者支持計劃正在推動對癌症治療的需求。

本報告提供全球腫瘤學治療藥市場相關調查分析,提供市場考察,市場動態,主要企業等相關的系統性資訊。

目錄

第1章 市場簡介

第2章 調查手法或前提條件

第3章 市場摘要

第4章 摘要整理

第5章 全球腫瘤學治療藥市場分析

第6章 市場考察:各治療類型

  • 化療
  • 標靶治療
  • 免疫療法
  • 荷爾蒙療法

第7章 市場考察:各癌症類型

  • 血液癌症
  • 肺癌
  • 大腸癌症
  • 前列腺癌症
  • 乳癌
  • 子宮頸癌症
  • 其他

第8章 市場考察:各給藥途徑

  • 口服
  • 非口服
  • 其他

第9章 市場考察:各終端用戶

  • 醫院
  • 專門診所
  • 癌症·放射治療中心
  • 其他

第10章 市場考察:各地區

  • 北美的腫瘤學治療藥市場
    • 美國
    • 加拿大
    • 其他北美
  • 歐洲的腫瘤學治療藥市場
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他的歐洲
  • 亞太地區的腫瘤學治療藥市場
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 其他的亞太地區
  • 其他地區的腫瘤學治療藥市場

第11章 需求面分析·供給面分析

第12章 價值鏈分析

第13章 全球腫瘤學治療藥市場趨勢·考察

第14章 全球腫瘤學治療藥的市場動態

  • 促進因素
  • 課題
  • 影響分析

第15章 全球腫瘤學治療藥市場機會

第16章 競爭模式

第17章 企業簡介

  • Amgen Inc.
  • Bayer AG
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • F Hoffmann-La Roche Ltd
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company

第18章 免責聲明

目錄
Product Code: UMHE21248

Oncology Therapeutics are mainly used for the treatment of cancer through surgery, chemotherapy, radiotherapy, or targeted therapy. Though there are many kinds of cancer, only a few dominates among the population. More than a million cancer cases are diagnosed every year and as per the American Cancer Society (2021), 1 in 3 people will be diagnosed with cancer in their lifetime. The demand for Oncology Therapeutics is increasing on account of increasing cancer prevalence, growing geriatric population, rise in R&D initiatives and private as well as public funding, and governments patient assistance programs. Moreover, the upsurge in the collaborations between pharmaceutical companies also propels the market growth. For instance, Merck Sharp & Dohme (MSD) have announced their research collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals for the development of small-molecule inhibitors against several drug targets. However, some of the restraints in the market include the high cost and the adverse effects associated with the use of oncology therapeutics. For instance, the second top-selling drug Herceptin 440 MG INJ. developed by Roche for the treatment of breast cancer costs around US$ 1,823.8 and the long-term use of this drug can lead to Congestive Heart Failure.

Based on Therapy Type, the market is fragmented into Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy. The main problem, particularly in cancer therapy is the damaging of normal tissue due to the high dose of chemotherapeutics. The main aim of Targeted Therapy is to concentrate the drug at the targeted site through passive or active targeting so that only a small amount of drug molecules can damage the normal tissue. The targeted therapy segment is expected to show the fastest growth in the upcoming years, owing to reduced toxicity, enhanced stability of the drug, and potential to deliver multiple drugs at the targeted site. The targeted therapy includes apoptosis inducers, angiogenesis inhibitors, gene expression modulators, hormone therapies, immunotherapies, and signal transduction inhibitors. For instance, small interfering (siRNA) based targeted drug delivery system is widely used for the treatment of non-small cell lung cancer (NSCLC), and as per the American Society of Clinical Oncology, NSCLC is the most common type of lung cancer which accounts for the 84% of all the lung cancer diagnosis in the US.

Based on Cancer Type, the market is fragmented into Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, and Others. Lung cancer is expected to record the highest growth in the upcoming years owing to its high prevalence in both the developed as well as developing countries. According to the American Society of Clinical Oncology, lung cancer is the second most common cancer and approximately 235,760 adults (119,100 men and 116,660 women) in the US will be diagnosed with lung cancer by the end of 2021. Based on the Route of Administration, the market is fragmented into Oral, Parenteral, and Others. The parenteral segment is expected to record the highest growth in the upcoming years owing to bypassing of first-pass metabolism, quick action, and high efficacy. Moreover, the rise in FDA approvals in the past few years for cancer chemotherapeutics also propels the market growth. For instance, FDA approved GSK's BLENREP anti-BCMA (B-cell maturation antigen) injection in 2021 as a monotherapy for the treatment of patients with relapsed or refractory multiple myeloma.

Based on End-user, the market is fragmented into Hospitals, Specialty Clinics, Cancer and Radiation Therapy centers. Cancer and Radiation Therapy centers are expected to dominate the market in the upcoming years owing to the large number of cancer treatments taking place at such centers across the globe. For instance, the Hospital of the University of PA, Abramson Cancer Center, United States is the best cancer center, with major focus on innovation, translational medicine, and cutting-edge technology. It consists of a Cancer risk evaluation program, Bone marrow and stem cell transplant program, GI Cancer Program, HIV oncology program Genitourinary cancer program, Proton Therapy, Melanoma, and Pigmented Lesion Program, and Telegenics Program.

For a better understanding of the market and adoption of the procedure, the report provides detailed analysis for major regions including North America (US, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, UK, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America dominates the Oncology Therapeutics market on account of the increasing prevalence of cancer cases and growing investment on R&D by Pharma companies. As per Breast Cancer.org, in 2021, approximately 281,550 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 49,290 new cases of non-invasive (in situ) breast cancer.

Some of the major players operating in the market include Amgen Inc., Bayer AG, Johnson & Johnson Services, Inc, Merck & Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Bristol-Myers Squibb Company, and Eli Lilly and Company. Several M&As along with partnerships have been undertaken by these players to boost their presence in different regions.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1 Market Definitions
  • 1.2 Limitations
  • 1.3 Stake Holders
  • 1.4 Currency Used in Report

2 RESEARCH PROCESS & RESEARCH METHODOLOGY

  • 2.1 Research Methodology of the Oncology Therapeutics Market

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL ONCOLOGY THERAPEUTICS MARKET ANALYSIS 2019-27F

6 MARKET INSIGHTS BY THERAPY TYPE

  • 6.1 Chemotherapy
  • 6.2 Targeted Therapy
  • 6.3 Immunotherapy
  • 6.4 Hormonal Therapy

7 MARKET INSIGHTS BY CANCER TYPE

  • 7.1 Blood Cancer
  • 7.2 Lung Cancer
  • 7.3 Colorectal Cancer
  • 7.4 Prostate Cancer
  • 7.5 Breast Cancer
  • 7.6 Cervical Cancer
  • 7.7 Others

8 MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

  • 8.1 Oral
  • 8.2 Parenteral
  • 8.3 Others

9 MARKET INSIGHTS BY END-USER

  • 9.1 Hospitals
  • 9.2 Specialty Clinics
  • 9.3 Cancer and Radiation Therapy Centers
  • 9.4 Other Ed-Users

10    MARKET INSIGHTS BY REGION

  • 10.1 NORTH AMERICA ONCOLOGY THERAPEUTICS MARKET
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Rest of North America
  • 10.2 EUROPE ONCOLOGY THERAPEUTICS MARKET
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 United Kingdom
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Rest of Europe
  • 10.3 ASIA PACIFIC ONCOLOGY THERAPEUTICS MARKET
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 Australia
    • 10.3.5 Rest of Asia Pacific
  • 10.4 REST OF WORLD ONCOLOGY THERAPEUTICS MARKET

11 Demand and Supply side analysis

  • 11.1 Demand Side Analysis
  • 11.2 Supply Side Analysis
    • 11.2.1 Top Product Launches
    • 11.2.2 Top Business Partnerships
    • 11.2.3 Top Business Expansions, Investments, and Divestitures
    • 11.2.4 Top Merger and Acquisitions

12 Value Chain Analysis

13 Global Oncology Therapeutics Market Trends & Insights

14 Global Oncology Therapeutics Market Dynamics

  • 14.1 Drivers
  • 14.2 Challenges
  • 14.3 Impact Analysis

15 Global Oncology Therapeutics Market Opportunities

16 Competitive Scenario

17 Company Profiled

  • 17.1 Amgen Inc.
  • 17.2 Bayer AG
  • 17.3 Johnson & Johnson Services, Inc.
  • 17.4 Novartis AG
  • 17.5 Pfizer Inc.
  • 17.6 F Hoffmann-La Roche Ltd
  • 17.7 AstraZeneca
  • 17.8 Bristol-Myers Squibb Company
  • 17.10 Eli Lilly and Company

18 Disclaimer